Establishment of the 2H-labeling Protocol at Pennington Biomedical Research Center
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 8/31/2018 |
| Start Date: | June 20, 2018 |
| End Date: | May 2019 |
| Contact: | Ursula White, Ph.D. |
| Email: | ursula.white@pbrc.edu |
| Phone: | 225-763-2656 |
Establishment of the 2H-labeling Protocol to Assess in Vivo Adipose Tissue Dynamics at PBRC
A method has been developed to measure in vivo adipose kinetics and turnover rates, which is
a substantive departure from previous indirect and in vitro approaches. This technique
involves drinking deuterium (2H)-labeled water, with an initial ramp-up to increase body
water 2H enrichment, followed by daily intake to maintain enrichment values. The 2H from the
heavy water is incorporated into the DNA of the dividing cells, as well as the lipid
component, providing measures of cell formation, lipid synthesis, and adipose turnover. The
objective of the proposed study is to enroll women who are overweight (sedentary or
physically active) in order to collect 2H-enriched adipose tissue specimens that will be
utilized to establish this innovative 2H-labeling protocol at Pennington Biomedical Research
Center. This study will also assess adipose kinetics in individuals with different levels of
physical activity to better understand the association between in vivo adipose cell kinetics,
physical activity, and metabolic health in humans.
a substantive departure from previous indirect and in vitro approaches. This technique
involves drinking deuterium (2H)-labeled water, with an initial ramp-up to increase body
water 2H enrichment, followed by daily intake to maintain enrichment values. The 2H from the
heavy water is incorporated into the DNA of the dividing cells, as well as the lipid
component, providing measures of cell formation, lipid synthesis, and adipose turnover. The
objective of the proposed study is to enroll women who are overweight (sedentary or
physically active) in order to collect 2H-enriched adipose tissue specimens that will be
utilized to establish this innovative 2H-labeling protocol at Pennington Biomedical Research
Center. This study will also assess adipose kinetics in individuals with different levels of
physical activity to better understand the association between in vivo adipose cell kinetics,
physical activity, and metabolic health in humans.
Inclusion Criteria:
- Pre-menopausal women
- 18-40 years of age
- BMI 25-29.9 kg/m2 (+/- 0.5 will be accepted)
- Are willing to drink deuterium-labeled water (2H2O) for 6 weeks
- Must be willing to comply with all study procedures, including adipose biopsies and a
DXA scan
- If applicable, hormonal contraception must have been started at least 2 months before
entering the study. If enrolled, subject must also agree to not alter hormonal birth
control method, dose, or regimen throughout the duration of the study
- If not using pharmaceutical (hormonal) contraception (i.e. birth control pills,
vaginal ring, injections, or implant), agree to use a double barrier method as a form
of birth control to prevent pregnancy
- Must be classified as either sedentary (achieve < 75 minutes of moderate-intensity or
< 37 minutes of vigorous-intensity aerobic physical activity per week) or very
physically active (achieve > 225 minutes of moderate-intensity or > 112 minutes of
vigorous-intensity aerobic physical activity per week). Simple questions to assess
physical activity level will be administered during the phone screening as well as the
clinic screening visit.
- If enrolled, agree to not alter dose, level, or regimen of physical activity
throughout the duration of the study
Exclusion Criteria:
- Unstable weight in the last 3 months (gain or loss >7 lb (3.2 kg)
- Significant changes in the diet or level of physical activity within the past month
- History of clinically diagnosed diabetes or a fasting blood glucose > 110 mg/dL
- An average screening blood pressure >140/90
- Have major organ disease (i.e. heart, kidney, lung, thyroid, or liver) or abnormal
liver enzymes that are, in the opinion of the medical investigator, clinically
significant and represent a problem for study inclusion.
- Self-reported positive test for human immunodeficiency virus, hepatitis B and
hepatitis C
- Chronic use of systemic glucocorticoids, systemic adrenergic-stimulating agents,
anti-psychotic/anti-depressant medications, thiazolidinediones and other medications
that may cause clinically significant weight gain or loss
- Chronic use of prescription or over-the-counter weight loss medications which, in the
opinion of the MI, will impact the study.
- Smoking or use of tobacco products in the last 3 months
- Pregnancy, breastfeeding, or planned pregnancy for the upcoming 2 months
- Previous bariatric or other surgeries for obesity
- Diagnosed psychotic conditions
We found this trial at
1
site
Pennington Biomedical Research Center Unlike other medical research facilities where science occurs in separate labs...
Click here to add this to my saved trials
